Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Zymeworks's Zanidatamab Zovodotin?
Zanidatamab Zovodotin is a monoclonal antibody conjugated commercialized by Zymeworks, with a leading Phase I program in Adenocarcinoma Of The...
Zanidatamab zovodotin by Zymeworks for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Zanidatamab zovodotin is under clinical development by Zymeworks and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...
Zanidatamab zovodotin by Zymeworks for Colorectal Cancer: Likelihood of Approval
Zanidatamab zovodotin is under clinical development by Zymeworks and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...